Patent ID: 8461193

Claim:
A method for treating a disease caused by and/or associated with a dysregulated protein kinase activity which comprises administering to a mammal in need thereof an effective amount of a compound of formula (I) as defined wherein: R is an optionally further substituted straight or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, heterocycloalkyl or aryl; R1 is selected from NHCOR4, NHSO 2 R10, NR5R6, R8R9N—C 1 -C 6 alkyl and R7O—C 1 -C 6 alkyl wherein: R4 is selected from an optionally further substituted heterocycloalkyl, aryl, NR8R9, and R7O—C 1 -C 6 alkyl; R5 is hydrogen, an optionally further substituted straight or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, heterocycloalkyl, aryl, R8R9N—C 2 -C 6 alkyl, and R7O —C 2 -C 6 alkyl, R6, is an optionally further substituted straight or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, heterocycloalkyl, aryl, R8R9N—C 2 -C 6 alkyl and R7O—C 2 -C 6 alkyl; R7 is selected from hydrogen, an optionally further substituted straight or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, heterocycloalkyl, aryl and R8R9N—C 2 -C 6 alkyl; R8 and R9, being the same or different, are independently selected from hydrogen, an optionally further substituted straight or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, heterocycloalkyl and aryl, or R8 and R9, taken together with the nitrogen atom to which they are bonded, form an optionally substituted heterocycloalkyl group; R10 is an optionally further substituted straight or branched C 1 -C 6 alkyl, C 3 -C 6 cycloalkyl, heterocycloalkyl or aryl; A, B, D and E represent a nitrogen atom, CH, CR2 or CR3, with a maximum of two of A, B, D and E representing a nitrogen atom, and with a maximum of two of A, B, D and E representing CR2 or CR3, wherein: R2 and R3, being the same or different, are independently selected from halogen, trifluoromethyl, nitro, OR7, NR8R9, an optionally further substituted straight or branched C 1 -C 6 alkyl, R8R9N—C 1 -C 6 alkyl and R7O—C 1 -C 6 alkyl, wherein R7, R8, and R9 are as defined above; Ra and Rb, being the same or different, are selected from hydrogen or methyl, with the proviso that: when A, D and E are CH, and B is CR2, wherein R2 is 4-methylpiperazine or morpholine, then R1 is not NHCOR4 wherein R4 is pyrrolidin-2-yl; or isomers, tautomers, carriers and pharmaceutically acceptable salt thereof, wherein the disease is selected from the group consisting of bladder cancer, blood cancer, bone cancer, brain cancer, breast cancer, cervical cancer, colon cancer, lung cancer, mesothelium cancer, ovarian cancer, pancreatic cancer, prostate cancer and skin cancer.